Talenom (TNOM) Q3 2026 earnings summary

Executive summary

• Q3 continuing-operations net sales rose 3.6% to €25.4m; comparable EBITDA increased 19.6% to €5.8m, with profitability improving across Finland, Sweden and Spain.

• Strategy execution focused on ONE Talenom, improving profitability in Sweden and Spain, organic and acquisition-led growth, software, and expanding AI use.

Financial highlights

• Q3 continuing-operations comparable net sales rose 3.6% to €25.4m; comparable EBITDA increased 19.6% to €5.8m.

• Q3 comparable operating profit increased 54.8% to €2.2m; continuing-operations net profit was €1.2m versus €0.6m.

• 9M continuing-operations comparable net sales grew 3.6% to €86.3m; comparable EBITDA rose 2.1% to €17.0m.

• 9M continuing-operations net profit fell 13.6% to €3.4m; EPS was €0.08 versus €0.09.

• Consolidated 9M net profit was €32.3m and EPS €0.71, including €28.9m profit from discontinued operations.

Outlook and guidance

• FY 2026 continuing-operations guidance unchanged: net sales of €110m–€120m and comparable EBITDA of €18m–€22m.

• Demand is expected to remain stable across operating countries; growth is expected to be mainly organic, with 2025 acquisitions also supporting sales.

• Profitability is expected to improve especially in Sweden and Spain; Sweden remains on track for positive EBITDA in 2026, while Spanish profitability is expected to improve as integration continues.

• AI transformation and the ONE Talenom operating model remain strategic priorities, with AI development planned to accelerate in Q4.